share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  10/23 20:05

Moomoo AI 已提取核心信息

On October 23, 2024, Clene Inc. disclosed the preliminary design of its RESTORE-ALS Phase 3 clinical trial for CNM-Au8 30 mg at the Annual NEALS Meeting. The trial is an international effort aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The details of the presentation were furnished in Exhibit 99.1, attached to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. clarified that the information provided, including the presentation, is not considered 'filed' under the Securities Exchange Act of 1934 and is not subject to its liabilities. Furthermore, the information should not be incorporated by reference into any future filings by the company, except as explicitly stated in such filings.
On October 23, 2024, Clene Inc. disclosed the preliminary design of its RESTORE-ALS Phase 3 clinical trial for CNM-Au8 30 mg at the Annual NEALS Meeting. The trial is an international effort aimed at addressing Amyotrophic Lateral Sclerosis (ALS). The details of the presentation were furnished in Exhibit 99.1, attached to the company's Current Report on Form 8-K filed with the SEC. Clene Inc. clarified that the information provided, including the presentation, is not considered 'filed' under the Securities Exchange Act of 1934 and is not subject to its liabilities. Furthermore, the information should not be incorporated by reference into any future filings by the company, except as explicitly stated in such filings.
2024年10月23日,Clene Inc.在年度NEALS会议上披露了其RESTORE-ALS第3期临床试验CNm-Au8 30毫克的初步设计。该试验是一个旨在解决肌萎缩性侧索硬化(ALS)的国际努力。演示内容的详细信息在附在公司提交给SEC的8-k表格的附件99.1中提供。Clene Inc.澄清,所提供的信息,包括演示内容,在1934年证券交易法案项下并不被视为“已提交”,也不受其责任约束。此外,该信息不应被引用到公司未来的任何备案文件中,除非在这些备案文件中明确声明。
2024年10月23日,Clene Inc.在年度NEALS会议上披露了其RESTORE-ALS第3期临床试验CNm-Au8 30毫克的初步设计。该试验是一个旨在解决肌萎缩性侧索硬化(ALS)的国际努力。演示内容的详细信息在附在公司提交给SEC的8-k表格的附件99.1中提供。Clene Inc.澄清,所提供的信息,包括演示内容,在1934年证券交易法案项下并不被视为“已提交”,也不受其责任约束。此外,该信息不应被引用到公司未来的任何备案文件中,除非在这些备案文件中明确声明。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息